Related Experiment Video
Updated: Jan 31, 2026

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Pre-hospital treatment duration and efficacy of remote ischaemic conditioning in the RESIST randomised-controlled
Aravind Ganesh1, David Gaist2, Boris Modrau3
1Calgary Stroke Program, Departments of Clinical Neurosciences, Community Health Sciences, and Radiology, the Hotchkiss Brain Institute, and the O'Brien Institute for Public Health, University of Calgary Cumming School of Medicine, Calgary, Canada.
Introduction:
Remote ischaemic conditioning (RIC) initiated pre-hospital did not improve 90-day functional outcomes after acute stroke in the RESIST trial. The duration of treatment pre-reperfusion modifies treatment effect for other neuroprotective therapies. We examined whether the effects of RIC might be modified by the duration of pre-hospital treatment.
Patients And Methods:
This post-hoc analysis of the RESIST randomised-controlled trial (ClinicalTrials.gov: NCT03481777) included patients who presented with pre-hospital stroke symptoms < 4 hours, randomised to RIC or sham, diagnosed with acute ischaemic stroke (AIS) or ICH (modified intention-to-treat [mITT] cohort). Patients were stratified by time from randomisation to hospital admission (ie, pre-hospital treatment duration). The primary outcome was shift in 90-day mRS; secondary outcomes were 90-day mRS 0-2 and 24-hour neurological improvement (NIHSS).
Results:
Among 902 mITT patients (AIS, n = 737; ICH, n = 165), median randomisation-to-admission time was 29.4 minutes (IQR: 19.6-39.4) and median onset-to-admission time was 88 minutes (IQR: 62.4-131.3). Across pre-hospital treatment duration strata, RIC conferred no significant benefit on 90-day mRS, mRS 0-2 or early NIHSS improvement in the combined, AIS or ICH populations. In patients with AIS receiving reperfusion therapy, stratification by transport time likewise revealed no efficacy differences. No significant interaction was observed between RIC and pre-hospital treatment duration for any outcome.
Conclusion:
Longer pre-hospital treatment duration was not associated with efficacy of RIC in the RESIST trial including in patients with AIS who received reperfusion therapies. Findings may not apply to settings where RIC could be routinely administered for longer periods. We found no treatment duration-dependent benefit of pre-hospital RIC, at least when durations are under an hour.
Related Concept Videos
Hospitals-II
Nurses that work in...
Treatment Resistant Cancers
Hospitals-I
Clinical Trials: Overview
Trial and Error and Algorithm
Self-Efficacy

